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Background: The International Ovarian Tumour Analysis (IOTA) group have developed the ADNEX (The Assessment of Different
NEoplasias in the adneXa) model to predict the risk that an ovarian mass is benign, borderline, stage I, stages II–IV or metastatic.
We aimed to externally validate the ADNEX model in the hands of examiners with varied training and experience.
Methods: This was a multicentre cross-sectional cohort study for diagnostic accuracy. Patients were recruited from three cancer
centres in Europe. Patients who underwent transvaginal ultrasonography and had a histological diagnosis of surgically removed
tissue were included. The diagnostic performance of the ADNEX model with and without the use of CA125 as a predictor was
calculated.
Results: Data from 610 women were analysed. The overall prevalence of malignancy was 30%. The area under the receiver
operator curve (AUC) for the ADNEX diagnostic performance to differentiate between benign and malignant masses was 0.937
(95% CI: 0.915–0.954) when CA125 was included, and 0.925 (95% CI: 0.902–0.943) when CA125 was excluded. The calibration plots
suggest good correspondence between the total predicted risk of malignancy and the observed proportion of malignancies. The
model showed good discrimination between the different subtypes.
Conclusions: The performance of the ADNEX model retains its performance on external validation in the hands of ultrasound
examiners with varied training and experience.
According to the latest statistics from the National Cancer Institute
in United States, 12.1 per 100 000 women developed ovarian cancer
per year between 2008 and 2012, with a mortality of 7.7 per
100 000 women (Howlader et al, 2015). The overall 5-year survival
is estimated to be B45.6% for all stages of the disease (Howlader
et al, 2015). However, for early localised ovarian cancers, the 5-year
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survival exceeds 90% (Howlader et al, 2015). A combination of
early diagnosis and centralised management are thought to be key
factors to optimise survival (Bristow et al, 2013, 2014; Howlader
et al, 2015). For early diagnosis, previous trials to evaluate ovarian
cancer screening have not been successful (Kobayashi et al, 2008;
Buys et al, 2011). However, recently, the United Kingdom
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
showed that screening using the risk of ovarian cancer algorithm
(ROCA) doubled the number of detected primary invasive
epithelial ovarian or tubal cancers (iEOCs) compared with a fixed
cutoff of CA125 (Menon et al, 2015). The researchers also reported
a significant mortality reduction with annual multimodal screening
(MMS) when prevalent cases were excluded. However, the effect of
this mortality reduction on final ovarian cancer screening cost
effectiveness requires longer-term follow-up of the study patients
(Jacobs et al, 2015).
A further important aspect of clinical management is that an
accurate diagnosis is made when a woman presents with an
ovarian mass. This is essential if women with cancer are to be
referred to specialist oncology services. The International Ovarian
Tumour Analysis group (IOTA) have developed and validated
models and rules to characterise ovarian masses as benign or
malignant (Timmerman et al, 2005, 2010a, b; Van Holsbeke et al,
2012). These models and rules have also been validated in the
hands of less experienced (level II) ultrasound examiners (Sayasneh
et al, 2013a,b).
The IOTA group has developed the multiclass ADNEX
(The Assessment of Different NEoplasias in the adneXa) model
that can differentiate between benign tumours, borderline tumours,
early-stage primary cancers, late-stage primary cancers (stages II–
IV) and secondary metastatic cancers (Van Calster et al, 2014). The
ADNEX is based on three clinical (including CA125) and six
ultrasound parameters (Van Calster et al, 2014), and also offers risk
calculation without CA125. The model was developed and
temporally validated using parameters collected by experienced
(or level III) ultrasound examiners, equivalent to a UK consultant
level with a special interest in gynaecological ultrasonography
(Education and Practical Standards Committee, European
Federation of Societies for Ultrasound in Medicine and Biology
(EFSUMB), 2006; Van Calster et al, 2014). This model should
facilitate the management of ovarian masses more efficiently as it
allows patients to be triaged to the correct management pathway,
whether for conservative follow-up, surgery at a general gynaecology
unit or management at high-volume specialised cancer centres.
Correctly classifying the subtype of malignancy is also of critical
importance as borderline ovarian tumours and early-stage ovarian
cancers can be treated less aggressively, leading to the possibility of
fertility preservation in younger women (Hennessy et al, 2009; Darai
et al, 2013). On the other hand, metastatic ovarian cancers should be
managed according to the origin of the primary cancer (Hennessy
et al, 2009).
The primary aim of this project was to externally validate the
ADNEX model. The secondary aim was to assess the performance of
the model by level II examiners with varied training (nonconsultant
doctors (MDs) and sonographers) (Education and Practical
Standards Committee, European Federation of Societies for
Ultrasound in Medicine and Biology (EFSUMB), 2006; Van
Calster et al, 2014). We hypothesised that the discriminatory
performance of ADNEX would be retained, that is, it would be
similar to the validation performance in the original ADNEX study.
MATERIALS AND METHODS
Setting and design. This was a multicentre cross-sectional cohort
study for diagnostic accuracy. Data were collected prospectively,
with the purpose of developing and validating ultrasound-based
prediction models from transvaginal ultrasound examinations
performed by level II ultrasound examiners (nonconsultant
gynaecology specialist, gynaecology trainees doctors and gynaecol-
ogy sonographers) (Education and Practical Standards Committee,
European Federation of Societies for Ultrasound in Medicine and
Biology (EFSUMB), 2006; The Royal College of Radiologists (RCR)
Board of the Faculty of Clinical Radiology, 2012). The ultrasound
examiners were blind to the results of the reference test, that is, the
final histological outcome or in the event of cancer the stage of the
disease The ADNEX model was applied by a single investigator
(AS) using a dedicated excel spreadsheet. Patients were recruited
from three cancer centres (Queen Charlotte’s Chelsea Hospital
(QCCH), London, UK; Princess Ann Hospital (PAH), South-
ampton, UK; and Garibaldi Nesima Hospital (GNH), Catania,
Italy). The study was approved as a service evaluation audit at the
UK centres and as a validation study by the hospital authority at
the Italian centre. The guidelines of the TRIPOD (Transparent
Reporting of a multivariable prediction model for Individual
Prognosis or Diagnosis) initiative were used (Collins et al, 2015).
Patients were recruited consecutively from September 2010 to
November 2014 at QCCH, from May 2012 to May 2014 at PAH
and from September 2012 to February 2015 at GNH. Patients at
QCCH and PAH were also recruited to the IOTA 4 study
(Sayasneh et al, 2013a,b). Transvaginal ultrasonography was
performed using the standardised approach previously published
by the IOTA group (Timmerman et al, 2000, 2010b). Transab-
dominal ultrasonography was undertaken when a large mass could
not be fully evaluated transvaginally (Timmerman et al, 2010b).
Participants and data collection. The inclusion criteria were
patients presenting with at least one adnexal mass who underwent
transvaginal ultrasonography at one of the participating centres.
For bilateral adnexal masses, the mass with the most complex
ultrasound features was included (Timmerman et al, 2000, 2010b).
If both masses had similar ultrasound morphology, the largest
mass or the one most easily accessible by ultrasonography was
included (Timmerman et al, 2010b).
The exclusion criteria were (1) pregnancy, (2) patients examined
by a consultant, (3) refusal of transvaginal ultrasonography, (4)
cytology rather than histology as an outcome and (5) failure to
undergo surgery within 120 days of the ultrasound examination. At
PAH, 8 cases were included in the final analysis, although they had
the ultrasound examination more than 120 days before surgery.
These cases underwent a CT scan within 120 days, confirming the
persistent presence of the mass.
The NHS Caldicott report guidelines were followed in all steps
of data handling (Great Britain; Department of Health, 1997).
At QCCH and GNH, a secure electronic data collection system was
used (Astraia Software, Munich, Germany). A unique identifier
was generated automatically for each patient’s record. Dedicated
data collection forms and excel sheets were used at PAH. Serum
CA125 was measured as per clinician’s discretion or clinical
practice in each centre, using Abbott Architect CA125 II (Abbott
Park, IL, USA) immunoassay kit at QCCH and GNH, and UniCel
DxI Immunoassay System (Beckman Coulter Inc., Brea, CA, USA)
Assay at PAH.
The ADNEX model. The ADNEX model contains three clinical
and six ultrasound predictors: age (in years), serum CA125 level
(Uml 1), type of centre (oncology centres vs other hospitals),
maximum diameter of lesion (in mm), proportion of solid tissue,
more than 10 cyst locules (yes or no), number of papillary
projections (0, 1, 2, 3 or 43) acoustic shadows (yes or no) and
ascites (yes or no) (Van Calster et al, 2014). Oncology centres were
defined as ‘tertiary referral centres with a specific gynaecology
oncology unit’. The proportion of solid tissue is obtained as the
ratio of the maximum diameter of the largest solid component and
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the maximum diameter of the lesion. The ADNEX model is
available online and in mobile applications (www.iotagroup.org/
adnexmodel/) (Van Calster et al, 2014). The ADNEX model can
still be calculated without including the serum CA125 value. In this
study we calculated the performance of the ADNEX model with
and without CA125. The temporal validation of the model with
CA125 in the original paper yielded an area under the receiver
operator curve (AUC) of 0.943 (0.934–0.952) to discriminate
benign from malignant tumours. The model without CA125 had
an AUC of 0.932 (0.922–0.941). Validation AUCs between all pairs
of the five categories varied between 0.71 (stage I cancer vs
secondary metastatic cancer) and 0.99 (benign tumours vs late
stage primary cancer). We applied the model exactly as presented
in the original publication, that is, without any changes to the
model formula or coefficients.
Reference tests. The reference standard was the histopathological
diagnosis of the mass after surgical removal. The excised tissues
underwent histological examination at the local centre. Tumours
were classified according to the WHO (World Health Organisa-
tion) classification of tumours and malignant tumours were staged
according to the FIGO (International Federation of Gynaecology
and Obstetrics) criteria (Tavassoli et al, 2003; Heintz et al, 2006).
Histological classification was performed without knowledge of the
ADNEX results or clinical and ultrasound findings for the patient.
The final diagnosis was categorised into five types: benign,
borderline, stage I invasive, stage II–IV invasive and secondary
metastatic cancer.
Statistical analysis. There were missing values for serum CA125
and for the presence of 410 cyst locules (loc10). Missing values
were handled differently for serum CA125 and loc10. The number
of missing values for the latter variable was small (3%), and hence
these were dealt with using single stochastic imputation based on
logistic regression. Missing loc10 values were predicted by a logistic
regression model with Firth correction with the following
predictors: age, maximum diameter of the lesion, proportion of
solid tissue, number of papillations, presence of acoustic shadows,
ascites, type of ovarian tumour and type of operator. The missing
serum CA125 values were handled with multiple stochastic
imputation using predictive mean matching regression. As the
distribution of serum CA125 was heavily skewed, the log–log
transformation of CA125 was used (i.e., log(log(CA125))). In this
imputation model, age, maximum diameter of the lesion,
proportion solid tissue, loc10, number of papillations, presence
of acoustic shadows, ascites, type of ovarian tumour, hospital and
operator type were used as predictors. Using this approach, the
missing values were replaced by 100 plausible values, leading to
100 completed data sets. Imputed values were back transformed to
the original scale. For the ADNEX model with CA125, each of the
100 completed data sets were analysed separately and their results
combined using Rubin’s Rules (Rubin, 1987).
External validation of the ADNEX model with and without
CA125 was performed by evaluating discrimination and calibration
performance. The AUC was calculated for the basic discrimination
between benign and malignant tumours using the total risk of
malignancy (i.e., the sum of the estimated risks of the four
malignant subtypes). The 95% confidence intervals for differences
in AUCs were computed based on 1000 bootstrap samples, where
for each bootstrap sample the same patients were selected across
the imputed data sets (Musoro et al, 2014). In addition, AUCs were
computed for each pair of tumour types using the conditional risk
method (Van Calster et al, 2012b). Finally, the polytomous
discrimination index was calculated (Van Calster et al, 2012a) that
estimates the average proportion of correctly classified patients by
the model when presented with five patients, one with each tumour
type. Sensitivity and specificity were calculated using a 1%, 5%,
10%, 15%, 20% and 30% cutoff denoting the total risk of
malignancy. Calibration of the predicted probabilities was assessed
through use of calibration plots that show the relation between the
observed and predicted probabilities for malignant tumours. The
calibration curve was estimated by using a loess smoother (Van
Calster et al, 2016).
RESULTS
During the study period, 751 women underwent ultrasonography
by level II examiners (one associate specialist in gynaecology,
12 resident gynaecology trainees and 29 sonographers) for a pelvic
mass and went through the surgical management pathway.
Of these, 141 women were excluded from the final analysis for
the following reasons: 65 women were examined by a consultant,
26 women had no histology result (14 only cytology, 12 no
cytology or histology), 24 women had surgery4120 days from the
characterising ultrasound scan, 15 women were pregnant, 5 women
only had a transabdominal scan, 5 women had no surgery
performed (declined or were not medically fit) and finally
1 woman who had a recurrence of cervical cancer in the pelvis a
few years after radical hysterectomy and underwent a bilateral
salpingo-oophorectomy was excluded as the tumour was not
considered adnexal. Supplementary Table 1 presents exclusions for
each centre. In the final analysis, 610 women were included
(Supplementary Figure 1). Of these patients, 142 (23%) had a
missing CA125 level and 17 (3%) had a missing value for loc10.
Supplementary Table 2 presents the numbers of missing values for
each of the study centres. The prevalence of malignancy was 30%
(n¼ 182), with 33% for QCCH, 32% for PAH and 19% for GNH.
There were 42 (7%) borderline tumours, 47 (8%) stage I primary
ovarian cancers, 69 (11%) stage II–IV primary ovarian cancers and
24 (4%) secondary metastatic cancers (see Supplementary Table 3
for a breakdown per centre). The median age was 47 years with
352 (58%) premenopausal and 258 (42%) postmenopausal women.
Table 1 shows descriptive statistics of the ADNEX predictors per
tumour subtype. Supplementary Tables 4–6 shows descriptive
statistics per centre.
The calibration plots suggest good correspondence between the
total predicted risk of malignancy and the observed proportion of
malignant tumours, both for the ADNEX model with and without
CA125 (Figure 1).
The AUC to differentiate between benign and malignant masses
was 0.937 (95% CI: 0.915–0.954) for ADNEX with CA125 and
0.925 (95% CI: 0.902–0943) for ADNEX without CA125 (Figure 2
and Table 2). The model with CA125 showed slightly better
performance (AUC difference: 0.012, 95% CI: 0.006–0.020). At risk
cutoffs of 1%, 10% and 30%, sensitivities were 100%, 97% and 86%
for ADNEX with CA125 (Table 3). Corresponding specificities
were 12%, 68% and 84%. As in the original study, centre
differences were observed with centre-specific AUCs for ADNEX
with CA125 that varied from 0.90 for PAH to 0.99 for GNH
(Table 2). The AUC was higher for premenopausal women (0.94)
than for postmenopausal women (0.90) (Table 2): 0.939 vs 0.899
for the model with CA125 (difference 0.04, 95% CI  0.009 to
0.084) and 0.935 vs 0.873 for the model without CA125 (difference
0.062, 95% CI 0.012 0.116).
When tumours were classified into benign, borderline, stage I
invasive, stages II–IV, invasive and secondary metastatic, the
model showed good discrimination between the different subtypes
(Table 4). For example, discrimination between benign and
stage II–IV tumours was near perfect for the model with CA125
(AUC 0.99). In comparison, the model had most difficulties
discriminating between borderline and stage I tumours
(AUC 0.78), though its performance is still good. The model
without CA125 mainly had lower AUCs for stage II IV tumours
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vs other groups, in particular vs secondary metastatic cancers
(AUC 0.88 for model with CA125, AUC 0.77 for model without
CA125). The polytomous discrimination index (PDI) was 0.58 for
ADNEX with CA125 and 0.52 for ADNEX without CA125
(Table 4), whereas PDI for random performance would be 0.20 for
five categories.
DISCUSSION
In this study, we have shown that in the hands of level II
ultrasound examiners, the ADNEX model was able to discriminate
between benign and malignant masses with a very similar level of
performance to that achieved by experienced ultrasound examiners
in the original ADNEX temporal validation study published by the
IOTA group (Van Calster et al, 2014). In our external validation
study using a 10% cutoff to define malignancy, the ADNEX model
achieved a sensitivity of 97.3% and a specificity of 67.7% compared
with 96.5% and 71.3% in the original study (Van Calster et al,
2014). The optimal cutoff for selecting patients for conservative
management may vary (e.g., between 1 and 5%) depending on the
health-care system, cost of surgery and surgical risk factors
(age, previous medical and surgical history). However, as this study
only included patients who underwent surgical management, we
cannot conclude which cutoff is optimal for conservative
management. This will be investigated in the IOTA5 study
(https://clinicaltrials.gov/ct2/show/NCT01698632). In contrast, in
a tertiary centre it may be preferable to have a lower false positive
rate, and a cutoff value of 30% may be more appropriate (Van
Calster et al, 2015).
To the best of our knowledge, this is the first external validation
study of the IOTA ADNEX model. Furthermore, the validation
was carried out by level II ultrasound examiners, whereas in the
previous IOTA development and temporal validation study (Van
Calster et al, 2014), the ultrasound scan parameters were collected
by experienced level III examiners. A strength of our study is that it
is multicentre, and as it includes level II examiners with varied
training and experience (sonographers and medical doctors), we
think the performance of the ADNEX model in this study is likely
to be generalisable. Another strength of our study is the robust
selection of the reference test, as only cases with a histological
outcome were included. However, this may also be seen as a
weakness in relation to the potential performance of the ADNEX
model for masses that are selected for conservative management as
these were not included in the study. This is an issue that applies to
most, if not all, of the diagnostic research carried out to date on
ovarian masses. The previously mentioned IOTA 5 study should
give us useful information on the diagnostic performance of
ADNEX and the long-term behaviour of these masses.
A potential limitation is the use of different assay kits for serum
CA125 measurements; however, the inconsistency in CA125 levels
Table 1. Descriptive information about the patients and masses included in the study according to tumour subtype
All patients Statistic
Benign
(n¼428)
Borderline
(n¼42)
Stage I OC
(n¼47)
Stage II–IV OC
(n¼69)
Secondary
metastasis
(n¼24)
Age, years Median (IQR) 43 (31–55) 47 (30–56) 57 (48–68) 62 (53–72) 55 (49–69)
CA125, IU l1 Median (IQR) 20 (12–39) 28 (21–64) 92 (35–209) 485 (136–1083) 66 (33–129)
Max lesion diameter, mm Median (IQR) 72 (51–95) 128 (91–174) 146 (109–180) 110 (76–140) 90 (73–135)
Presence of solid parts N (%) 142 (33%) 30 (71%) 46 (98%) 69 (100%) 22 (92%)
Proportion of solid tissue, if present Median (IQR) 0.36 (0.18–0.78) 0.37 (0.19–0.47) 0.43 (0.30–0.67) 0.59 (0.41–1.00) 1.00 (0.58–1.00)
More than 10 locules N (%) 31 (7%) 14 (33%) 13 (28%) 11 (16%) 7 (29%)
Number of papillations
0 N (%) 371 (87%) 26 (62%) 33 (70%) 52 (75%) 21 (88%)
1 N (%) 31 (7%) 6 (14%) 1 (2%) 8 (12%) 0 (0%)
2 N (%) 12 (3%) 2 (5%) 5 (11%) 1 (1%) 2 (8%)
3 N (%) 3 (1%) 2 (5%) 2 (4%) 0 (0%) 1 (4%)
43 N (%) 11 (3%) 6 (14%) 6 (13%) 8 (12%) 0 (0%)
Acoustic shadows N (%) 94 (22%) 0 (0%) 6 (13%) 1 (1%) 1 (4%)
Ascites N (%) 6 (1%) 1 (2%) 3 (6%) 23 (33%) 7 (29%)
Abbreviations: CA125¼ cancer antigen 125; IQR¼ interquartile range; OC¼ovarian cancer.
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Figure 1. (A) Calibration plot for the ADNEX model with serum CA125. (B) Calibration plot for the ADNEX model without serum CA125.
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resulting from this is thought to be limited (Davelaar et al, 1998).
Furthermore, the variance in CA125 assay kits used in the study is
a reflection of clinical reality and again means results are more
likely to be reproducible (Van Calster et al, 2014). A further
possible limitation of the study is that all three participating
hospitals were referral centres for gynaecological cancers, resulting
in there being a relatively high prevalence of malignant disease in
the study population. Accordingly, it is possible that our findings
may have limitations when trying to predict test performance
either in primary care or secondary gynaecology units. However, it
should be noted that in the original ADNEX study the prevalence
of malignancy ranged from 0 to 66% in the 24 participating centres
(Van Calster et al, 2014), and hence this makes it more likely that
results will be generalisable. Furthermore, ADNEX explicitly
corrects its prediction for type of centre (oncology centres vs
other centres). In this sense, the potential for selection bias is
accounted for by the model.
Finally, having no centralised histopathology review in our
study may have led to bias. For example, distinguishing borderline
tumours from benign tumours or even stage I cancer may be
challenging for pathologists, where disagreement can occur and
this may give inaccurate diagnostic performance results for the
ADNEX model in these cases (Van Calster et al, 2014). However,
as all the histopathology departments involved in this study were
tertiary referral centres for gynaecological cancers, in the event of a
discrepancy (including discrepancies in the referring units) a local
review at the tertiary centre would have been held to resolve the
disagreement. Furthermore, centralised review of pathology was
discontinued in IOTA studies as it was shown in initial studies that
there were minimal differences between local and central reports
(Timmerman et al, 2005).
It is worth noting that we have observed variation in the
ADNEX performance between centres that is comparable to the
one observed in the original IOTA validation study (Van Calster
et al, 2014). This variation could be explained by the differences in
Table 3. The overall sensitivity and specificity (benign vs
malignant) of the ADNEX model with and without the
inclusion of serum CA125
Cutoff
Patients with
riskXcutoff,
N (%)
Sensitivity with
95% CI
Specificity with
95% CI
ADNEX with CA125
1% 559 (91.6%) 100.0% (97.4–100.0) 11.9% (9.1–15.5)
3% 479 (78.5%) 100.0% (97.4–100.0) 30.6% (26.3–35.3)
5% 383 (62.8%) 99.0% (94.9–99.8) 53.2% (48.2–58.1)
10% 315 (51.6%) 97.3% (93.5–98.9) 67.7% (63.0–72.0)
15% 281 (46.1%) 94.4% (90.0–97.0) 75.2% (70.7–79.2)
20% 253 (41.5%) 90.6% (85.2–94.1) 79.3% (75.1–83.0)
30% 226 (37.0%) 86.3% (80.4–90.6) 83.9% (80.1–87.2)
ADNEX without CA125
1% 557 (91.3%) 100.0% (97.4–100.0) 12.4% (9.5–16.0)
3% 490 (80.3%) 100.0% (97.4–100.0) 28.0% (23.9–32.6)
5% 374 (61.3%) 98.9% (95.7–99.7) 54.7% (49.9–59.3)
10% 317 (52.0%) 96.7% (92.9–98.5) 67.1% (62.5–71.3)
15% 289 (47.4%) 94.5% (90.1–97.0) 72.7% (68.2–76.7)
20% 261 (42.8%) 90.7% (85.5–94.1) 77.6% (73.4–81.3)
30% 225 (36.9%) 84.6% (78.6–89.2) 83.4% (80.0–86.6)
Abbreviations: ADNEX¼The Assessment of Different NEoplasias in the adneXa; CA125¼
cancer antigen 125; CI¼ confidence interval. When using a 1% or 3% cutoff, confidence
limits are calculated through use of Wilson’s score confidence interval method with
continuity correction (Newcombe, 1998). For the other cutoffs, confidence limits are
calculated using logistic regression to combine results after multiple imputation.
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Figure 2. Receiver operating curves for the ADNEX model with and
without serum CA125 levels to discriminate between benign and
malignant masses.
Table 4. Pairwise AUCs and PDI of the ADNEX model with
and without serum CA125
Discrimination measure ADNEX with
CA125
ADNEX
without
CA125
Polytomous discrimination index (PDI) 0.59 0.52
AUC benign vs borderline 0.88 0.88
AUC benign vs stage I OC 0.95 0.94
AUC benign vs stage II–IV OC 0.99 0.97
AUC benign vs secondary metastasis 0.96 0.95
AUC borderline vs stage I OC 0.78 0.78
AUC borderline vs stage II–IV OC 0.94 0.91
AUC borderline vs secondary metastasis 0.92 0.93
AUC stage I OC vs stage II–IV OC 0.83 0.79
AUC stage I OC vs secondary metastasis 0.81 0.83
AUC stage II–IV OC vs secondary metastasis 0.88 0.77
Abbreviations: ADNEX¼The Assessment of Different NEoplasias in the adneXa; AUC¼
area under the receiver operating curve; CA125¼ cancer antigen 125; OC¼ovarian cancer.
Table 2. The area under the receiver operator curve for the
discrimination between benign and malignant lesions for
ADNEX with and without CA125 according to type of centre
and sonographer
ADNEX with
CA125
ADNEX without
CA125
Subgroup AUC 95% CI AUC 95% CI
All patients 0.937 0.915–0.954 0.925 0.902–0.943
Centre
QCCH 0.942 0.913–0.962 0.931 0.900–0.953
PAH 0.900 0.841–0.938 0.889 0.828–0.930
GNH 0.990 0.959–0.998 0.983 0.950–0.995
Operator profession
MD 0.939 0.917–0.956 0.924 0.900–0.943
Sonographer 0.912 0.809–0.962 0.916 0.818–0.964
Menopausal status
Premenopausal 0.939 0.901–0.963 0.935 0.901–0.958
Postmenopausal 0.899 0.855–0.931 0.873 0.824–0.910
Abbreviations: ADNEX¼The Assessment of Different NEoplasias in the adneXa; AUC¼
area under the receiver operating curve; CA125¼ cancer antigen 125; CI¼ confidence
interval; MD¼medically qualified doctor; QCCH¼Queen Charlotte’s and Chelsea
Hospital; PAH¼Princess Anne Hospital; GNH¼Garibaldi Nesima Hospital.
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the case mix between these centres with a higher number of
secondary metastatic cancers in PAH compared with QCCH and
GNH. It is important to investigate heterogeneity between centres,
but this data set is not ideal for this objective because this requires
a larger database derived from a large number of centres.
In our study, the classification of the level of experience of the
ultrasound examiners (level II) was based on the recommendations
published by the European Federation of Societies for Ultrasound
in Medicine and Biology (Education and Practical Standards
Committee, European Federation of Societies for Ultrasound in
Medicine and Biology (EFSUMB), 2006) and by the Royal College
of Radiologists (The Royal College of Radiologists (RCR) Board of
the Faculty of Clinical Radiology, 2012). As guidance, a level III
examiner in the United Kingdom equates to a consultant with a
special interest in gynaecological ultrasonography (The Royal
College of Radiologists (RCR) Board of the Faculty of Clinical
Radiology, 2012). We acknowledge that this approach has
limitations as some level II examiners may have similar levels of
competence to someone with level III experience. However, it is
acknowledged that the boundaries between these levels can be
difficult to distinguish and may overlap (The Royal College of
Radiologists (RCR) Board of the Faculty of Clinical Radiology,
2012). In our study, similar to previous findings when the IOTA
model LR2 was validated in the hands of level II examiners
(Sayasneh et al, 2013b), we found the AUC for the ADNEX model
was slightly higher when the scans were performed by doctors
compared with sonographers (Table 2).
By characterising the type of malignancy (borderline, primary stage I
cancer, primary stage II–IV cancer or secondary metastatic), the
ADNEXmodel offers the possibility of a more personalised diagnosis in
the event of an ovarian mass. This potentially may enable fertility
preserving surgery in some women, help plan the most appropriate
surgical approach (laparoscopy or laparotomy) in others or direct
attention to the primary site of malignancy in the event of metastasis.
Although the ADNEX model gives absolute risks ratios, relative risk
ratios can be computed to give a comparison with the background risk
for individual patient (Van Calster et al, 2015). External validation is a
critical step for any diagnostic test before it can be introduced into
clinical practice. We have shown that the performance of the ADNEX
model is retained in units with different patient populations to the
original study, and that it performs well in the hands of examiners with
different levels of experience and background training. Our findings
suggest that the ADNEX model has the potential to improve
management decisions in daily clinical practice for women with
adnexal tumours.
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